Patents by Inventor Harry Randall Munson

Harry Randall Munson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
    Patent number: 8716317
    Abstract: The invention relates to Sulfonamides with heterocycle and oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: May 6, 2014
    Assignee: Sanofi
    Inventors: Stefanie Keil, Matthias Urmann, Maike Glien, Hans Matter, Harry Randall Munson, Jr., Ulrike Wendler
  • SULFONAMIDES WITH HETEROCYCLE AND OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20120172400
    Abstract: The invention relates to Sulfonamides with heterocycle and oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Application
    Filed: May 22, 2009
    Publication date: July 5, 2012
    Applicant: SANOFI-AVENTIS
    Inventors: Stefanie Keil, Matthias Urmann, Wolfgang Wendler, Ulrike Wendler, Maike Glien, Hans Matter, Harry Randall Munson, JR.
  • Pyrimidine amide compounds as PGDS inhibitors
    Patent number: 8202863
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2, R3 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: June 19, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Suzanne C. Aldous, John Ziqi Jiang, Jinqi Lu, Liang Ma, Lan Mu, Harry Randall Munson, Jeffrey Stephen Sabol, Sukanthini Thurairatnam, Christopher Loren Vandeusen
  • PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS
    Publication number: 20080227782
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2, R3 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: April 4, 2008
    Publication date: September 18, 2008
    Applicant: AVENTIS PHARMACEUTICALS INC
    Inventors: Suzanne C. Aldous, John Ziqi Jiang, Jinqi Lu, Liang Ma, Lan Mu, Harry Randall Munson, Jeffrey Stephen Sabol, Sukanthini Thurairatnam, Christopher Loren Vandeusen